# Methods in ENZYMOLOGY

# Volume 444 Angiogenesis: *In Vivo* Systems, Part A

Edited by David A. Cheresh



# METHODS IN ENZYMOLOGY

Angiogenesis: *In Vivo* Systems, Part A

# METHODS IN ENZYMOLOGY

Editors-in-Chief

#### JOHN N. ABELSON AND MELVIN I. SIMON

Division of Biology California Institute of Technology Pasadena, California

Founding Editors

SIDNEY P. COLOWICK AND NATHAN O. KAPLAN

# METHODS IN ENZYMOLOGY Angiogenesis: *In Vivo* Systems, Part A

EDITED BY DAVID A. CHERESH University of California, San Diego Moore's Cancer Center La Jolla, CA, USA



AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 32 Jamestown Road, London NW1 7BY, UK

Copyright © 2008, Elsevier Inc. All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (www.copyright.com), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2008 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0076-6879/2008 \$35.00

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail: permissions@elsevier. com. You may also complete your request on-line via the Elsevier homepage (http://elsevier.com), by selecting "Support & Contact" then "Copyright and Permission" and then "Obtaining Permissions."

For information on all Elsevier Academic Press publications visit our Web site at elsevierdirect.com

ISBN-13: 978-0-12-374313-8

PRINTED IN THE UNITED STATES OF AMERICA 08 09 10 11 9 8 7 6 5 4 3 2 1

Working together to grow libraries in developing countries

www.elsevier.com  $\mid$  www.bookaid.org  $\mid$  www.sabre.org

ELSEVIER BOOK AID Sabre Foundation

## CONTENTS

Contributors Preface		xi xv	
Volu	Volumes in Series		
1.	Molecular Mechanism of Type IV Collagen–Derived Endogenous Inhibitors of Angiogenesis Vesselina G. Cooke and Raghu Kalluri	1	
	<ol> <li>Introduction</li> <li>Molecular Mechanism of Type IV Collagen–Derived</li> </ol>	2	
	Endogenous Inhibitors 3. Assessing the Role of Type IV Collagen–Derived Endogenous Inhibitor During Angiogenesis	3 13	
	4. Concluding Remarks	16	
	References	17	
2.	Chick Embryo Chorioallantoic Membrane Models to Quantify Angiogenesis Induced by Inflammatory and Tumor Cells or Purified Effector Molecules Elena I. Deryugina and James P. Quigley	21	
	1. Introduction	22	
	<ol> <li>Overview of CAM Angiogenesis Models</li> <li>Assessing the Role of Purified Effector Molecules and Cells in</li> </ol>	24	
	Angiogenesis Using CAM Collagen Onplant Model	30	
	<ol> <li>CAM Collagen Onplant Assay Protocol</li> <li>Validation of CAM Angiogenesis Findings in Collagen Implant</li> </ol>	31	
	Mouse Model	38	
	Acknowledgment	39	
	References	39	
3.	The Adenoviral Vector Angiogenesis/Lymphangiogenesis Assay Janice A. Nagy, Shou-Ching Shih, Wendy H. Wong, Ann M. Dvorak, and Harold F. Dvorak	43	
	<ol> <li>Introduction</li> <li>Methods</li> </ol>	44 46	

v

	3. Blood Vessels Induced by Ad-VEGF-A <sup>164</sup>	53
	4. Giant Lymphatics Induced by Ad-VEGF-A <sup>164</sup>	58
	5. Use of Ear Angiogenesis Assay to Evaluate Antiangiogenesis Drugs	59
	6. Commentary and Future Perspectives	60
	Acknowledgments	61
	References	61
4.	Using the Zebrafish to Study Vessel Formation	65
	Mary C. McKinney and Brant M. Weinstein	
	1. Introduction	66
	2. Methods for Functional Manipulation of Zebrafish	68
	3. Methods for Visualizing Vessels in Zebrafish	76
	4. Conclusion	91
	Acknowledgment	91
	References	91
5.	Evaluating Vascular Leak In Vivo	99
	Sara M. Weis	
	1. Introduction	100
	2. Mechanisms of Vascular Leak	100
	3. Consequences of Vascular Leak in Disease	101
	4. Models to Study Vascular Leak In Vivo	102
	5. Concluding Remarks	112
	Acknowledgments	112
	References	112
6.	Ocular Models of Angiogenesis	115
	Edith Aguilar, Michael I. Dorrell, David Friedlander, Ruth A. Jacobson, Audra Johnson, Valentina Marchetti, Stacey K. Moreno, Matthew R. Ritter, and Martin Friedlander	
	1. Introduction	116
	2. Techniques Commonly Used in Ocular Angiogenesis Protocols	118
	3. Corneal Micropocket Assay	120
	4. Neonatal Mouse Retinal Developmental Angiogenesis Model	124
	5. Oxygen-Induced Retinopathy Model	128
	6. Laser-induced Retinal and Choroidal Neovascularization Models	135
	7. Retinal Vascular Permeability Model	138
	8. Three-Dimensional In Vivo Imaging of the Mouse Ocular Vasculature	141
	9. Cell-based Models and Ocular Angiogenesis	151
	10. Concluding Remarks	154
	References	154

7.	Mouse Models of Ischemic Angiogenesis and Ischemia- Reperfusion Injury	
	Joshua I. Greenberg, Ahmed Suliman, Samuel Barillas, and Niren Angle	
	1. Introduction	160
	2. Overview of Methods in Hindlimb I/R Injury	161
	3. Evaluating Hindlimb Ischemia/Reperfusion Injury	164
	<ol> <li>Overview of Methods in Chronic Hindlimb Ischemia</li> <li>Overview of Murine Models of Acute Myocardial Infarction</li> </ol>	167
	and Myocardial I/R Injury	171
	6. Conclusion	173
	References	174
8.	Noninvasive Imaging of Blood Vessels	175
	Milan Makale	
	1. Introduction	176
	2. Methods	181
	References	197
9.	Intravital Videomicroscopy in Angiogenesis Research	201
	Ian C. MacDonald and Ann F. Chambers	
	1. Introduction	202
	2. Methods	206
	3. Summary	228
	Acknowledgments	228
	References	228
10.	In Vivo Measurements of Blood Flow and Glial Cell Function	
	with Two-Photon Laser-Scanning Microscopy	231
	Fritjof Helmchen and David Kleinfeld	
	1. Introduction	232
	2. Two-Photon Microscopy of Fluorescent Labels as a Tool	
	for Brain Imaging	234
	3. Photoprocesses for Targeted Disruption of Vascular Flow	247
	4. Outlook	248
	Acknowledgments	251
	References	251

11.	The Role of Bone Marrow–Derived Cells in Tumor Angiogenesis and Metastatic Progression	255
	Marianna Papaspyridonos and David Lyden	
	1. The Angiogenic Switch	256
	<ol> <li>Origin of Angiogenic Endothelial Cells</li> <li>Bone-Marrow–Derived Cells: Endothelial and Hematopoietic</li> </ol>	256
	Progenitor Cells	257
	4. Bone Marrow–Cell Mobilization in Response to Tumor Factors	258
	5. Contribution of BMDCs in Tumor Angiogenesis	258
	6. EPCs and HPCs are Required for Tumor Angiogenesis	259
	7. Cooperation between BM-Derived Hematopoietic and Endothelial Precursors	260
	8. VEGFR1 <sup>+</sup> HPCs Define the Premetastatic Niche	260
	9. Stromal Cells: Carcinoma-Associated Fibroblasts (CAFs)	261
	10. Activation of the SDF-1–CXCR4 Pathway in Mobilization of	205
	Proangiogenic Cells	263
	11. Future Directions	265
	References	266
17	Structure of Microwander Naturalis in Constin Humantansian	271
12.	Structure of Microvascular Networks in Genetic Hypertension Walter L. Murfee and Geert W. Schmid-Schönbein	271
	waller L. Mullee and Geert W. Schnid-Schönbein	
	1. Introduction	272
	2. Methods	273
	3. Results	275
	4. Discussion	279
	5. Summary	282
	References	282
13.	Oxygen as a Direct and Indirect Biological Determinant	
	in the Vasculature	285
	Yan Huang and Frank J. Giordano	
	1. Introduction	286
	2. Mechanisms of Oxygen Sensing and Transduction into Vascular	
	Biological Responses	286
	3. Physiological, Pathophysiological, and Clinical Settings in Which	202
	Oxygen Levels Influence the Vasculature 4. Summary	293 300
	4. Summary References	300
	Neterences	500

14.	Me	asuring Intratumoral Microvessel Density	305
	Noe	el Weidner	
	1.	Introduction	305
	2.	Measuring Intratumoral Microvessel Density	307
	3.	Highlighting Microvessels for Microvessel Counting	310
	4.	Histological Quantitation of Tumor Angiogenesis	312
	5.	Novel In Vivo Methods for Measuring Microvessel Density	314
	Ref	erences	315
Autł	nor li	ndex	325
Sub	bject Index		

This page intentionally left blank

## CONTRIBUTORS

#### **Edith Aguilar**

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### **Niren Angle**

Section of Vascular and Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Diego, San Diego, California

#### Samuel Barillas

Section of Vascular and Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Diego, San Diego, California

#### Ann F. Chambers

Department of Oncology, University of Western Ontario, London, Ontario, Canada

#### Vesselina G. Cooke

Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

#### Elena I. Deryugina

The Scripps Research Institute, La Jolla, California

#### Michael I. Dorrell

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Ann M. Dvorak

Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

#### Harold F. Dvorak

Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

#### **David Friedlander**

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Martin Friedlander

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Frank J. Giordano

Cardiovascular Medicine, Department of Medicine, and Vascular Biology and Translation Program, Yale University School of Medicine, New Haven, Connecticut

#### Joshua I. Greenberg

Section of Vascular and Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Diego, San Diego, California

#### **Fritjof Helmchen**

Department of Neurophysiology, Brain Research Institute, University of Zurich, Zurich, Switzerland

#### Yan Huang

Cardiovascular Medicine, Department of Medicine, and Vascular Biology and Translation Program, Yale University School of Medicine, New Haven, Connecticut

#### **Ruth A. Jacobson**

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Audra Johnson

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Raghu Kalluri

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, and Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, and Harvard–MIT Division of Health Sciences and Technology, Boston, Massachusetts

#### **David Kleinfeld**

Department of Physics, University of California, San Diego, La Jolla, California

#### **David Lyden**

Department of Pediatrics and Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, and Memorial Sloan-Kettering Cancer Center, New York

#### Ian C. MacDonald

Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada

#### Milan Makale

Moores Cancer Center, University of California, San Diego, La Jolla, California

#### Valentina Marchetti

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Mary C. McKinney

Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, Bethesda, Maryland

#### Stacey K. Moreno

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Walter L. Murfee

Assistant Professor Department of Biomedical Engineering, Tulane University, New Orleans, Louisiana

#### Janice A. Nagy

Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

#### Marianna Papaspyridonos

Department of Pediatrics and Department of Cell and Developmental Biology, Weill Cornell Medical College, New York

#### James P. Quigley

The Scripps Research Institute, La Jolla, California

#### Matthew R. Ritter

Department of Cell Biology, The Scripps Research Institute, La Jolla, California

#### Geert W. Schmid-Schönbein

Professor Department of Bioengineering, University of California, San Diego, La Jolla, California

#### **Shou-Ching Shih**

Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

#### Ahmed Suliman

Section of Vascular and Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Diego, San Diego, California

#### Noel Weidner

Department of Pathology, University of California, San Diego, San Diego, California

#### Brant M. Weinstein

Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, Bethesda, Maryland

#### Sara M. Weis

Moores Cancer Center, University of California, San Diego, La Jolla, California

#### Wendy H. Wong

Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

### Preface

### A TRIBUTE TO DR. JUDAH FOLKMAN

The field of angiogenesis has recently lost its pioneer and leader, Dr. Judah Folkman. This was a tremendous loss to many of us who knew him and to the field in general. Dr. Folkman inspired a generation of scientists in efforts to translate basic discoveries toward new therapeutics for a wide range of diseases including cancer, blinding eye disease, and inflammatory disease. Due in large part to Dr. Folkman's efforts and direction, we now have the first generation of therapeutics that disrupt angiogenesis in patients suffering from cancer and macular degeneration. While Dr. Folkman clearly passed away before his time, he did live long enough to observe that many thousands of patients are now better off due to antiangiogenic therapy.

I had a rather interesting initiation to the field of antiangiogenesis that was wholly inspired by Dr. Folkman. In the mid-1980s as a junior faculty at the Scripps Research Institute, I was studying what many of us in the field were beginning to appreciate were a family of cell adhesion receptors, later termed "integrins." I had developed a monoclonal antibody (LM609) to the vitronectin receptor later referred to as integrin  $\alpha \nu \beta 3$ . During the course of my work, LM609 was used to stain a variety of diseased and normal tissues. To my surprise, LM609 reacted strongly with blood vessels in tumors and inflammatory sites, but failed to react with blood vessels in normal tissues. After seeing this result, I began to read up on the emerging field of angiogenesis research. It was clear that most of the literature in the field came from Dr. Folkman or one of his disciples. I immediately contacted Dr. Folkman. By the time I finished describing our results, I realized that he was excited as I was about our studies. In fact, before I could ask him any questions, he suggested that I visit his lab to learn the chick chorioallantoic membrane (CAM) assay to determine whether LM609 might have an impact on angiogenesis in a quantitative animal model.

Naturally I arranged a trip to the Folkman lab within the next couple of weeks. I had never been to Harvard, and was a bit intimidated by the place. I introduced myself to his administrative assistant, who welcomed me and indicated that Dr. Folkman was expecting me. Within minutes, Dr. Folkman, clad in a lab coat greeted me and suggested that we get started. At this point, I assumed he was going to introduce me to one of his students or technicians who would then proceed to show me the CAM assay step by step. To my surprise, Dr. Folkman led me to a hood, sat down,

and immediately started to instruct me in how to induce angiogenesis on the CAM. In fact, the next thing I knew, I was sitting at the hood next to Dr. Folkman going through the procedure in detail. Therefore, I can say I learned the technique from the master. Ultimately, Dr. Folkman introduced me to several members of the Folkman lab, including Drs. Donald Inber, Pat D'Amore, and Mike Klagsburn. I remember how enthusiastic and communicative all of these folks were. In fact, I am happy to say that I still maintain close contact with them and have had many opportunities over the years to discuss science and reminisce about the past. In fact, Don, Pat, and Mike have all kindly contributed chapters to *Methods in Enzymology* volumes on angiogenesis.

While on the airline flight home from the Folkman lab, I began to realize that my career was about to take a change in course. From that point forward, I began to focus on the role of adhesion receptors in angiogenesis and began to realize that blocking angiogenesis with integrin antagonists could have a very impressive impact on the growth of tumors in mice. Importantly, two of the agents we developed, including humanized LM609, have shown clinical activity in patients with late-stage cancer.

Since my initiation to the field, I have since followed Dr. Folkman's work and have attended dozens of his lectures. Listening to a Folkman lecture is like watching one of your favorite movies—you can watch it over and over again and still find something interesting to think about. It was difficult for anyone to attend his lecture and not come away excited about science in general and angiogenesis in particular. The field of angiogenesis has matured over the past 25 years due in large part to Dr. Folkman's drive, enthusiasm, perseverance, and kindness. Dr. Folkman's leadership has helped to recruit many scientists and physicians from the academic and private sectors to focus on new approaches to develop angiogenesis inhibitors.

In the early days, there were a limited number of technological approaches to measure and study angiogenesis. The CAM assay was among the first quantitative approaches to measure the growth of newly forming blood vessels. From this humble beginning, the field has exploded and as a result we now have a wide range of techniques, approaches, and animal models designed to monitor and study the growth of new blood vessels in development, tissue remodeling, and disease. These methods are described in detail in this volume by many of the current leaders of the field.

### METHODS IN ENZYMOLOGY

VOLUME I. Preparation and Assay of Enzymes Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME II. Preparation and Assay of Enzymes Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME III. Preparation and Assay of Substrates Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME IV. Special Techniques for the Enzymologist Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME V. Preparation and Assay of Enzymes Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME VI. Preparation and Assay of Enzymes (Continued) Preparation and Assay of Substrates Special Techniques Edited by Sidney P. Colowick and Nathan O. Kaplan VOLUME VII. Cumulative Subject Index Edited by Sidney P. Colowick and Nathan O. Kaplan **VOLUME VIII.** Complex Carbohydrates Edited by ELIZABETH F. NEUFELD AND VICTOR GINSBURG VOLUME IX. Carbohydrate Metabolism Edited by WILLIS A. WOOD VOLUME X. Oxidation and Phosphorylation Edited by Ronald W. Estabrook and Maynard E. Pullman **VOLUME XI. Enzyme Structure** Edited by C. H. W. HIRS VOLUME XII. Nucleic Acids (Parts A and B) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME XIII. Citric Acid Cycle Edited by J. M. LOWENSTEIN VOLUME XIV. Lipids Edited by J. M. LOWENSTEIN VOLUME XV. Steroids and Terpenoids Edited by RAYMOND B. CLAYTON

**VOLUME XVI.** Fast Reactions Edited by KENNETH KUSTIN VOLUME XVII. Metabolism of Amino Acids and Amines (Parts A and B) Edited by HERBERT TABOR AND CELIA WHITE TABOR VOLUME XVIII. Vitamins and Coenzymes (Parts A, B, and C) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME XIX. Proteolytic Enzymes Edited by Gertrude E. Perlmann and Laszlo Lorand VOLUME XX. Nucleic Acids and Protein Synthesis (Part C) Edited by Kivie Moldave and Lawrence Grossman VOLUME XXI. Nucleic Acids (Part D) Edited by Lawrence Grossman and Kivie Moldave VOLUME XXII. Enzyme Purification and Related Techniques Edited by WILLIAM B. JAKOBY VOLUME XXIII. Photosynthesis (Part A) Edited by ANTHONY SAN PIETRO VOLUME XXIV. Photosynthesis and Nitrogen Fixation (Part B) Edited by ANTHONY SAN PIETRO VOLUME XXV. Enzyme Structure (Part B) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVI. Enzyme Structure (Part C) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVII. Enzyme Structure (Part D) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVIII. Complex Carbohydrates (Part B) Edited by VICTOR GINSBURG VOLUME XXIX. Nucleic Acids and Protein Synthesis (Part E) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME XXX. Nucleic Acids and Protein Synthesis (Part F) Edited by Kivie Moldave and Lawrence Grossman VOLUME XXXI. Biomembranes (Part A) Edited by Sidney Fleischer and Lester Packer VOLUME XXXII. Biomembranes (Part B) Edited by Sidney Fleischer and Lester Packer VOLUME XXXIII. Cumulative Subject Index Volumes I-XXX Edited by MARTHA G. DENNIS AND EDWARD A. DENNIS VOLUME XXXIV. Affinity Techniques (Enzyme Purification: Part B) Edited by William B. JAKOBY AND MEIR WILCHEK

VOLUME XXXV. Lipids (Part B) Edited by JOHN M. LOWENSTEIN VOLUME XXXVI. Hormone Action (Part A: Steroid Hormones) Edited by Bert W. O'MALLEY AND JOEL G. HARDMAN VOLUME XXXVII. Hormone Action (Part B: Peptide Hormones) Edited by Bert W. O'MALLEY AND JOEL G. HARDMAN VOLUME XXXVIII. Hormone Action (Part C: Cyclic Nucleotides) Edited by Joel G. HARDMAN AND BERT W. O'MALLEY VOLUME XXXIX. Hormone Action (Part D: Isolated Cells, Tissues, and Organ Systems) Edited by Joel G. HARDMAN AND BERT W. O'MALLEY VOLUME XL. Hormone Action (Part E: Nuclear Structure and Function) Edited by Bert W. O'MALLEY AND JOEL G. HARDMAN VOLUME XLI. Carbohydrate Metabolism (Part B) Edited by W. A. WOOD VOLUME XLII. Carbohydrate Metabolism (Part C) Edited by W. A. WOOD **VOLUME XLIII.** Antibiotics Edited by JOHN H. HASH VOLUME XLIV. Immobilized Enzymes Edited by KLAUS MOSBACH VOLUME XLV. Proteolytic Enzymes (Part B) Edited by LASZLO LORAND VOLUME XLVI. Affinity Labeling Edited by William B. JAKOBY AND MEIR WILCHEK VOLUME XLVII. Enzyme Structure (Part E) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XLVIII. Enzyme Structure (Part F) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XLIX. Enzyme Structure (Part G) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME L. Complex Carbohydrates (Part C) Edited by VICTOR GINSBURG VOLUME LI. Purine and Pyrimidine Nucleotide Metabolism Edited by PATRICIA A. HOFFEE AND MARY ELLEN JONES VOLUME LII. Biomembranes (Part C: Biological Oxidations) Edited by Sidney Fleischer and Lester Packer

VOLUME LIII. Biomembranes (Part D: Biological Oxidations) Edited by Sidney Fleischer and Lester Packer VOLUME LIV. Biomembranes (Part E: Biological Oxidations) Edited by Sidney Fleischer and Lester Packer VOLUME LV. Biomembranes (Part F: Bioenergetics) Edited by Sidney Fleischer and Lester Packer VOLUME LVI. Biomembranes (Part G: Bioenergetics) Edited by Sidney Fleischer and Lester Packer VOLUME LVII. Bioluminescence and Chemiluminescence Edited by MARLENE A. DELUCA VOLUME LVIII. Cell Culture Edited by William B. JAKOBY AND IRA PASTAN VOLUME LIX. Nucleic Acids and Protein Synthesis (Part G) Edited by Kivie Moldave and Lawrence Grossman VOLUME LX. Nucleic Acids and Protein Synthesis (Part H) Edited by Kivie Moldave and Lawrence Grossman VOLUME 61. Enzyme Structure (Part H) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 62. Vitamins and Coenzymes (Part D) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 63. Enzyme Kinetics and Mechanism (Part A: Initial Rate and Inhibitor Methods) Edited by DANIEL L. PURICH VOLUME 64. Enzyme Kinetics and Mechanism (Part B: Isotopic Probes and Complex Enzyme Systems) *Edited by* DANIEL L. PURICH VOLUME 65. Nucleic Acids (Part I) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME 66. Vitamins and Coenzymes (Part E) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 67. Vitamins and Coenzymes (Part F) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 68. Recombinant DNA Edited by RAY WU VOLUME 69. Photosynthesis and Nitrogen Fixation (Part C) Edited by ANTHONY SAN PIETRO VOLUME 70. Immunochemical Techniques (Part A) Edited by Helen Van Vunakis and John J. Langone